This article was originally published in The Gray Sheet
Executive SummaryRefractive laser manufacturer LaserSight will pay the firm an undisclosed royalty for each LASIK procedure performed with the company's LaserScan system, following the settlement of a patent infringement suit filed by Visx in Delaware federal court in November 1999. In addition, Visx has licensed patents '418 and '388 to LaserSight and Visx purchased patent '135 as part of the agreement. The case is scheduled to go to trial June 13
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.